Ayse Uneri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayse Uneri has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Kimberly F. Raab-Graham
Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, USA
6 shared publications Colin J McArdle
Department of Translational Neuroscience, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA
3 shared publications- Farr Niere
Wake Forest School of Medicine, Winston Salem, NC USA
3 shared publications Suzanne Craft
Department of Gerontology and Geriatric Medicine, Wake Forest Alzheimer's Disease Research Center, Winston-Salem, NC, USA
3 shared publications- Chelcie F. Heaney
Wake Forest School of Medicine
2 shared publications Jeffrey L. Weiner
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC, 27157, United States
2 shared publications
Latest Publications
- Open Access
- 14 February 2026
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 50, 101617
IGROOVE: Protocol for a randomized, controlled, single-blind trial of dance intervention in older adults with subjective cognitive decline
- 14 February 2026
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 50, 101617
Open AccessIGROOVE: Protocol for a randomized, controlled, single-blind trial of dance intervention in older adults with subjective cognitive decline
- 29 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 102 (3) , 763-777
DJ-1-mediated repression of the RNA-binding protein FMRP is predicted to impact known Alzheimer's disease-related protein networks
Background: RNA-binding proteins (RBPs) modulate the synaptic proteome and are instrumental in maintaining synaptic homeostasis. Moreover, aberrant expression of an RBP in a disease state would have deleterious downstream effects on synaptic function. While many underlying mechanisms of synaptic dysfunction in Alzheimer's disease (AD) have been proposed, the contribution of RBPs has been relatively unexplored. Objective: To investigate alterations in RBP-messenger RNA (mRNA) interactions in AD, and its overall impact on the disease-related proteome. Methods: We first utilized RNA-immunoprecipitation to investigate interactions between RBP, DJ-1 (Parkinson's Disease protein 7) and target mRNAs in controls and AD. Surface Sensing of Translation – Proximity Ligation Assay (SUnSET-PLA) and western blotting additionally quantified alterations in mRNA translation and protein expression of DJ-1 targets. Finally, we utilized an unbiased bioinformatic approach that connects AD-related pathways to two RBPs, DJ-1 and FMRP (Fragile X messenger ribonucleoprotein 1). Results: We find that oligomeric DJ-1 in AD donor synapses were less dynamic in their ability to bind and unbind mRNA compared to synapses from cognitively unimpaired, neuropathologically-verified controls. Furthermore, we find that DJ-1 associates with the mRNA coding for FMRP, Fmr1 , leading to its reduced synaptic expression in AD. Through the construction of protein-protein interaction networks, aberrant expression of DJ-1 and FMRP are predicted to lead to the upregulation of key AD-related pathways, such as thyroid hormone stimulating pathway, autophagy, and ubiquitin mediated proteolysis. Conclusions: DJ-1 and FMRP are novel targets that may restore established neurobiological mechanisms underlying AD.
- 29 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 102 (3) , 763-777
DJ-1-mediated repression of the RNA-binding protein FMRP is predicted to impact known Alzheimer's disease-related protein networks
Background: RNA-binding proteins (RBPs) modulate the synaptic proteome and are instrumental in maintaining synaptic homeostasis. Moreover, aberrant expression of an RBP in a disease state would have deleterious downstream effects on synaptic function. While many underlying mechanisms of synaptic dysfunction in Alzheimer's disease (AD) have been proposed, the contribution of RBPs has been relatively unexplored. Objective: To investigate alterations in RBP-messenger RNA (mRNA) interactions in AD, and its overall impact on the disease-related proteome. Methods: We first utilized RNA-immunoprecipitation to investigate interactions between RBP, DJ-1 (Parkinson's Disease protein 7) and target mRNAs in controls and AD. Surface Sensing of Translation – Proximity Ligation Assay (SUnSET-PLA) and western blotting additionally quantified alterations in mRNA translation and protein expression of DJ-1 targets. Finally, we utilized an unbiased bioinformatic approach that connects AD-related pathways to two RBPs, DJ-1 and FMRP (Fragile X messenger ribonucleoprotein 1). Results: We find that oligomeric DJ-1 in AD donor synapses were less dynamic in their ability to bind and unbind mRNA compared to synapses from cognitively unimpaired, neuropathologically-verified controls. Furthermore, we find that DJ-1 associates with the mRNA coding for FMRP, Fmr1 , leading to its reduced synaptic expression in AD. Through the construction of protein-protein interaction networks, aberrant expression of DJ-1 and FMRP are predicted to lead to the upregulation of key AD-related pathways, such as thyroid hormone stimulating pathway, autophagy, and ubiquitin mediated proteolysis. Conclusions: DJ-1 and FMRP are novel targets that may restore established neurobiological mechanisms underlying AD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Exaggerated translational repression of FMRP in AD synapses
Background: Alzheimer’s Disease (AD) is a progressive cognitive disorder where synapse loss has been well documented. Identifying and restoring molecular targets that are involved in synapse loss is crucial in restoring balanced synaptic function and communication. FMRP is an RNA‐binding protein that is essential protein for synapse formation and stability, and is understudied in AD. Understanding how FMRP may be dysregulated at the synaptic level in AD is integral in developing treatments for AD.Method: RNA‐immunoprecipitation of DJ‐1 was performed to detect whether DJ‐1 associates with the mRNA coding for FMRP. Synaptoneurosomes and postsynaptic densities we isolated from AD rodent model APP/PS1deltaE9 and postmortem human AD patients, as well as from appropriate controls, and performed Western blotting to analyze FMRP protein expression. SUnSET‐PLA assay was utilized to determine de novo synthesis of FMRP in DJ‐1 overexpression.Result: DJ‐1, which is an RNA‐binding protein that is overexpressed in AD synapses, associates with Fmr1, the mRNA coding for the protein FMRP. FMRP expression is decreased in AD synapses, as well as postsynaptic densities. When DJ‐1 is overexpressed in WT cultures, there is less newly synthesized FMRP.Conclusion: Here, we show that DJ‐1 associates with Fmr1, which codes for another RNA‐binding protein, FMRP. DJ‐1 and FMRP are aberrantly expressed in AD synapses. DJ‐1 is overexpressed in AD synapses while FMRP is reduced. Furthermore, when DJ‐1 is overexpressed in WT cultures, FMRP synthesis is reduced, suggesting that DJ‐1 is a translational repressor of FMRP. Therefore, the reduction of FMRP in AD synapses are due to overexpression of DJ‐1, and the rescue of FMRP expression could potentially rescue synaptic loss in AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessExaggerated translational repression of FMRP in AD synapses
Background: Alzheimer’s Disease (AD) is a progressive cognitive disorder where synapse loss has been well documented. Identifying and restoring molecular targets that are involved in synapse loss is crucial in restoring balanced synaptic function and communication. FMRP is an RNA‐binding protein that is essential protein for synapse formation and stability, and is understudied in AD. Understanding how FMRP may be dysregulated at the synaptic level in AD is integral in developing treatments for AD.Method: RNA‐immunoprecipitation of DJ‐1 was performed to detect whether DJ‐1 associates with the mRNA coding for FMRP. Synaptoneurosomes and postsynaptic densities we isolated from AD rodent model APP/PS1deltaE9 and postmortem human AD patients, as well as from appropriate controls, and performed Western blotting to analyze FMRP protein expression. SUnSET‐PLA assay was utilized to determine de novo synthesis of FMRP in DJ‐1 overexpression.Result: DJ‐1, which is an RNA‐binding protein that is overexpressed in AD synapses, associates with Fmr1, the mRNA coding for the protein FMRP. FMRP expression is decreased in AD synapses, as well as postsynaptic densities. When DJ‐1 is overexpressed in WT cultures, there is less newly synthesized FMRP.Conclusion: Here, we show that DJ‐1 associates with Fmr1, which codes for another RNA‐binding protein, FMRP. DJ‐1 and FMRP are aberrantly expressed in AD synapses. DJ‐1 is overexpressed in AD synapses while FMRP is reduced. Furthermore, when DJ‐1 is overexpressed in WT cultures, FMRP synthesis is reduced, suggesting that DJ‐1 is a translational repressor of FMRP. Therefore, the reduction of FMRP in AD synapses are due to overexpression of DJ‐1, and the rescue of FMRP expression could potentially rescue synaptic loss in AD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
GABAB receptor activation promotes synaptic resilience in Alzheimer’s disease
Background: Hyperexcitability and glutamate excitotoxicity are the primary contributors towards synapse loss in Alzheimer’s disease (AD). The goal of this project is to examine how other neurotransmitter systems, such as the inhibitory GABAergic system, are responding to hyperexcitability in AD. Therefore, we examined the role of metabotropic GABAB receptors (GABABRs) towards synapse loss.Methods: Primary hippocampal neurons were cultured from both wildtype (WT) and transgenic APP/PS1 mice. In addition, treatment of non‐transgenic hippocampal neurons with Aβ oligomers (500nM) were used as another model of AD‐related pathology. Immunocytochemistry was used to determine the dendric expression of GABAB1R and GABAB2R, the two principal subunits of GABABRs. To examine changes in GABABR function, a calcium imaging protocol was utilized to quantify changes in calcium florescence following GABABR activation with baclofen (50μM). To understand whether GABABR activation is protective against synaptic loss in AD, APP/PS1 hippocampal neurons were treated with 50μM baclofen (GABABR agonist), 100μM CGP35348 (GABABR antagonist), or vehicle. This study used both colocalization of presynaptic (Synapsin‐1) and postsynaptic (PSD95) markers as well as a novel method, DetectSyn, to quantify changes in synaptic density.Results: Dendritic GABAB1R and GABAB2R expression is upregulated in APP/PS1 hippocampal neurons as compared to WT. Non‐transgenic neurons treated with Aβ‐oligomers also show upregulations in GABAB2R, with no changes in GABAB1R. Treating WT neurons with baclofen resulted in an approximate 10% decrease in calcium florescence. The same treatment applied to APP/PS1 neurons resulted in a significantly greater decrease (∼40%) in calcium florescence. Activating GABABRs in APP/PS1 neurons increased synaptic density as compared to vehicle treated neurons. This was indicated by a greater Pearson’s coefficient between Synapsin‐1 and PSD95, as well as a greater number of DetectSyn‐PLA puncta. Antagonizing GABABRs in APP/PS1 neurons failed to rescue synaptic density (no changes in Pearson’s coefficient/DetectSyn‐PLA puncta) when compared to vehicle treated neurons.Conclusions: Under pathological conditions, upregulation and activation of GABABRs serves as a potential mechanism to combat against hyperexcitability, therefore preventing hippocampal synaptic loss in AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessGABAB receptor activation promotes synaptic resilience in Alzheimer’s disease
Background: Hyperexcitability and glutamate excitotoxicity are the primary contributors towards synapse loss in Alzheimer’s disease (AD). The goal of this project is to examine how other neurotransmitter systems, such as the inhibitory GABAergic system, are responding to hyperexcitability in AD. Therefore, we examined the role of metabotropic GABAB receptors (GABABRs) towards synapse loss.Methods: Primary hippocampal neurons were cultured from both wildtype (WT) and transgenic APP/PS1 mice. In addition, treatment of non‐transgenic hippocampal neurons with Aβ oligomers (500nM) were used as another model of AD‐related pathology. Immunocytochemistry was used to determine the dendric expression of GABAB1R and GABAB2R, the two principal subunits of GABABRs. To examine changes in GABABR function, a calcium imaging protocol was utilized to quantify changes in calcium florescence following GABABR activation with baclofen (50μM). To understand whether GABABR activation is protective against synaptic loss in AD, APP/PS1 hippocampal neurons were treated with 50μM baclofen (GABABR agonist), 100μM CGP35348 (GABABR antagonist), or vehicle. This study used both colocalization of presynaptic (Synapsin‐1) and postsynaptic (PSD95) markers as well as a novel method, DetectSyn, to quantify changes in synaptic density.Results: Dendritic GABAB1R and GABAB2R expression is upregulated in APP/PS1 hippocampal neurons as compared to WT. Non‐transgenic neurons treated with Aβ‐oligomers also show upregulations in GABAB2R, with no changes in GABAB1R. Treating WT neurons with baclofen resulted in an approximate 10% decrease in calcium florescence. The same treatment applied to APP/PS1 neurons resulted in a significantly greater decrease (∼40%) in calcium florescence. Activating GABABRs in APP/PS1 neurons increased synaptic density as compared to vehicle treated neurons. This was indicated by a greater Pearson’s coefficient between Synapsin‐1 and PSD95, as well as a greater number of DetectSyn‐PLA puncta. Antagonizing GABABRs in APP/PS1 neurons failed to rescue synaptic density (no changes in Pearson’s coefficient/DetectSyn‐PLA puncta) when compared to vehicle treated neurons.Conclusions: Under pathological conditions, upregulation and activation of GABABRs serves as a potential mechanism to combat against hyperexcitability, therefore preventing hippocampal synaptic loss in AD.
- Open Access
- 30 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (45)
Aberrant DJ-1 expression underlies L-type calcium channel hypoactivity in dendrites in tuberous sclerosis complex and Alzheimer’s disease
L-type voltage-gated calcium (Ca 2+ ) channels (L-VGCC) dysfunction is implicated in several neurological and psychiatric diseases. While a popular therapeutic target, it is unknown whether molecular mechanisms leading to disrupted L-VGCC across neurodegenerative disorders are conserved. Importantly, L-VGCC integrate synaptic signals to facilitate a plethora of cellular mechanisms; however, mechanisms that regulate L-VGCC channel density and subcellular compartmentalization are understudied. Herein, we report that in disease models with overactive mammalian target of rapamycin complex 1 (mTORC1) signaling (or mTORopathies), deficits in dendritic L-VGCC activity are associated with increased expression of the RNA-binding protein (RBP) Parkinsonism-associated deglycase (DJ-1). DJ-1 binds the mRNA coding for the alpha and auxiliary Ca 2+ channel subunits Ca V 1.2 and α2δ2, and represses their mRNA translation, only in the disease states, specifically preclinical models of tuberous sclerosis complex (TSC) and Alzheimer’s disease (AD). In agreement, DJ-1-mediated repression of Ca V 1.2/α2δ2 protein synthesis in dendrites is exaggerated in mouse models of AD and TSC, resulting in deficits in dendritic L-VGCC calcium activity. Finding of DJ-1-regulated L-VGCC activity in dendrites in TSC and AD provides a unique signaling pathway that can be targeted in clinical mTORopathies.
- 30 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (45)
Open AccessAberrant DJ-1 expression underlies L-type calcium channel hypoactivity in dendrites in tuberous sclerosis complex and Alzheimer’s disease
L-type voltage-gated calcium (Ca 2+ ) channels (L-VGCC) dysfunction is implicated in several neurological and psychiatric diseases. While a popular therapeutic target, it is unknown whether molecular mechanisms leading to disrupted L-VGCC across neurodegenerative disorders are conserved. Importantly, L-VGCC integrate synaptic signals to facilitate a plethora of cellular mechanisms; however, mechanisms that regulate L-VGCC channel density and subcellular compartmentalization are understudied. Herein, we report that in disease models with overactive mammalian target of rapamycin complex 1 (mTORC1) signaling (or mTORopathies), deficits in dendritic L-VGCC activity are associated with increased expression of the RNA-binding protein (RBP) Parkinsonism-associated deglycase (DJ-1). DJ-1 binds the mRNA coding for the alpha and auxiliary Ca 2+ channel subunits Ca V 1.2 and α2δ2, and represses their mRNA translation, only in the disease states, specifically preclinical models of tuberous sclerosis complex (TSC) and Alzheimer’s disease (AD). In agreement, DJ-1-mediated repression of Ca V 1.2/α2δ2 protein synthesis in dendrites is exaggerated in mouse models of AD and TSC, resulting in deficits in dendritic L-VGCC calcium activity. Finding of DJ-1-regulated L-VGCC activity in dendrites in TSC and AD provides a unique signaling pathway that can be targeted in clinical mTORopathies.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S2) , e058602
mRNA‐Binding Protein DJ‐1 as a pivotal protein in AD pathology
Background: Alzheimer’s Disease (AD) is a complex neurodegenerative disorder of the synapse, characterized by the accumulation of amyloid beta plaques and neurofibrillary tangles. We have recently shown that Parkinson Protein 7, DJ‐1, is upregulated by mTORC1 activity, and is a translational hub that is predicted to coordinate the expression of a population of synaptic proteins (Niere et al., 2016). This cellular function of DJ‐1 is mediated through its RNA‐binding properties, yet many of its target mRNAs are unidentified, and the effects of this protein‐mRNA association are not well‐defined.Method: Synaptically increased DJ‐1 expression was determined by Western blotting of synaptoneurosomes from AD patients (Niere et al., 2020), and APP/PS1 and P301S mouse models of AD. DJ‐1 target mRNAs were first bioinformatically identified using a modified consensus sequence of DJ‐1 protein (van der Brug et al., 2008), and confirmed via RNA‐immunoprecipitation of DJ‐1 from WT mouse cortices. FMR1KO mouse cortices were used as a negative control.Result: Synaptic DJ‐1 expression is increased in a preclinical mouse model of AD exhibiting plaque pathology, and AD patients. Interestingly, there is no change in synaptic DJ‐1 levels in the P301S mouse model, which presents neurofibrillary tangles. We bioinformatically identified that mRNA coding for the RNA‐binding protein FMRP, and tau‐tubulin kinase 1 (TTBK1), known for phosphorylating pathogenic tau, as potential targets for DJ‐1, and confirmed it via RNA‐immunoprecipitation. Furthermore, the protein levels of FMRP is significantly decreased in the synapses of AD patients and APP/PS1 mice, while there is no change in the P301S model consistent with no change in DJ‐1 expression.Conclusion: Decrease in FMRP in AD synapses where DJ‐1 expression is high suggests that DJ‐1 is a translational repressor of FMRP. FMRP binds to the mRNA of amyloid precursor protein (APP), the building block of amyloid beta plaques. Therefore, DJ‐1’s capacity to bind both Fmr1, coding for a protein which is known as a translational suppressor of APP mRNA (Borreca et al., 2016), and Ttbk1, a tau kinase involved in tau phosphorylation and aggregation (Sato et al., 2006) suggests that DJ‐1 might be at the crossroads of both AD hallmark pathologies.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S2) , e058602
mRNA‐Binding Protein DJ‐1 as a pivotal protein in AD pathology
Background: Alzheimer’s Disease (AD) is a complex neurodegenerative disorder of the synapse, characterized by the accumulation of amyloid beta plaques and neurofibrillary tangles. We have recently shown that Parkinson Protein 7, DJ‐1, is upregulated by mTORC1 activity, and is a translational hub that is predicted to coordinate the expression of a population of synaptic proteins (Niere et al., 2016). This cellular function of DJ‐1 is mediated through its RNA‐binding properties, yet many of its target mRNAs are unidentified, and the effects of this protein‐mRNA association are not well‐defined.Method: Synaptically increased DJ‐1 expression was determined by Western blotting of synaptoneurosomes from AD patients (Niere et al., 2020), and APP/PS1 and P301S mouse models of AD. DJ‐1 target mRNAs were first bioinformatically identified using a modified consensus sequence of DJ‐1 protein (van der Brug et al., 2008), and confirmed via RNA‐immunoprecipitation of DJ‐1 from WT mouse cortices. FMR1KO mouse cortices were used as a negative control.Result: Synaptic DJ‐1 expression is increased in a preclinical mouse model of AD exhibiting plaque pathology, and AD patients. Interestingly, there is no change in synaptic DJ‐1 levels in the P301S mouse model, which presents neurofibrillary tangles. We bioinformatically identified that mRNA coding for the RNA‐binding protein FMRP, and tau‐tubulin kinase 1 (TTBK1), known for phosphorylating pathogenic tau, as potential targets for DJ‐1, and confirmed it via RNA‐immunoprecipitation. Furthermore, the protein levels of FMRP is significantly decreased in the synapses of AD patients and APP/PS1 mice, while there is no change in the P301S model consistent with no change in DJ‐1 expression.Conclusion: Decrease in FMRP in AD synapses where DJ‐1 expression is high suggests that DJ‐1 is a translational repressor of FMRP. FMRP binds to the mRNA of amyloid precursor protein (APP), the building block of amyloid beta plaques. Therefore, DJ‐1’s capacity to bind both Fmr1, coding for a protein which is known as a translational suppressor of APP mRNA (Borreca et al., 2016), and Ttbk1, a tau kinase involved in tau phosphorylation and aggregation (Sato et al., 2006) suggests that DJ‐1 might be at the crossroads of both AD hallmark pathologies.
- Open Access
Role of FMRP in rapid antidepressant effects and synapse regulation
Rapid antidepressants are novel treatments for major depressive disorder (MDD) and work by blocking N-methyl-aspartate receptors (NMDAR), which, in turn, activate the protein synthesis pathway regulated by mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Our recent work demonstrates that the RNA-binding protein Fragile X Mental Retardation Protein (FMRP) is downregulated in dendrites upon treatment with a rapid antidepressant. Here, we show that the behavioral effects of the rapid antidepressant Ro-25-6981 require FMRP expression, and treatment promotes differential mRNA binding to FMRP in an mTORC1-dependent manner. Further, these mRNAs are identified to regulate transsynaptic signaling. Using a novel technique, we show that synapse formation underlying the behavioral effects of Ro-25-6981 requires GABA B R-mediated mTORC1 activity in WT animals. Finally, we demonstrate that in an animal model that lacks FMRP expression and has clinical relevance for Fragile X Syndrome (FXS), GABA B R activity is detrimental to the effects of Ro-25-6981. These effects are rescued with the combined therapy of blocking GABA B Rs and NMDARs, indicating that rapid antidepressants alone may not be an effective treatment for people with comorbid FXS and MDD.
Open AccessRole of FMRP in rapid antidepressant effects and synapse regulation
Rapid antidepressants are novel treatments for major depressive disorder (MDD) and work by blocking N-methyl-aspartate receptors (NMDAR), which, in turn, activate the protein synthesis pathway regulated by mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Our recent work demonstrates that the RNA-binding protein Fragile X Mental Retardation Protein (FMRP) is downregulated in dendrites upon treatment with a rapid antidepressant. Here, we show that the behavioral effects of the rapid antidepressant Ro-25-6981 require FMRP expression, and treatment promotes differential mRNA binding to FMRP in an mTORC1-dependent manner. Further, these mRNAs are identified to regulate transsynaptic signaling. Using a novel technique, we show that synapse formation underlying the behavioral effects of Ro-25-6981 requires GABA B R-mediated mTORC1 activity in WT animals. Finally, we demonstrate that in an animal model that lacks FMRP expression and has clinical relevance for Fragile X Syndrome (FXS), GABA B R activity is detrimental to the effects of Ro-25-6981. These effects are rescued with the combined therapy of blocking GABA B Rs and NMDARs, indicating that rapid antidepressants alone may not be an effective treatment for people with comorbid FXS and MDD.